About Sailybio

Shanghai Sailybio Biomedical Co., Ltd. has deep expertise in immunology and cell technology, and is a "Specialized, Refined, Distinctive and Innovative" (SRDI) enterprise focused on providing R&D services for innovative drug development. The company's predecessor was Shanghai Saily Biotech Co., Ltd., founded in 2015, which later underwent a strategic integration with Shanghai Xuanfeng Biotech Co., Ltd. and was renamed accordingly—marking a further expansion of its business scope and a comprehensive upgrade of its integrated service capabilities.

Founded more than ten years ago, the company has consistently operated in compliance with regulations and maintained stable operations, building an integrated service system covering cell isolation services, in vitro efficacy evaluation, clinical project management, and the supply of testing products. The company has its own in-house R&D laboratory platform, has established a BSL-2 pathogenic microorganism laboratory, and has obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification. Centered on technological innovation and grounded in compliant service delivery, the company—through its professional technical capabilities and reliable service quality—has served numerous leading domestic and international biopharmaceutical companies and research institutions, deeply empowering many innovative drug R&D pipelines. It has earned widespread trust from clients, helping them accelerate the development of innovative drugs and advance more new drugs from early-stage research into clinical application, ultimately improving patient health.